SynthesisInternational journal of molecular sciences2020
Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.
Synthesis in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 5 syntheses or guidelines pooled it, 148 citations in OpenAlex.
- Determination of the Combined Effects of Asian Herbal Medicine with Calcium and/or Vitamin D Supplements on Bone Mineral Density in Primary Osteoporosis: A Systematic Review and Meta-Analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Pooled it
- Serum osteocalcin levels are inversely associated with UACR in Chinese DKD patients: a meta-analysis of 20 clinical studies.Frontiers in endocrinology · 2024Pooled it
- Interventions to reduce falls among dialysis patients: a systematic review.BMC nephrology · 2023Pooled it
- Comorbidity in bullous pemphigoid: up-date and clinical implications.Frontiers in immunology · 2023Pooled it
- "Sarcopenia and risk of osteoporosis, falls and bone fractures in patients with chronic kidney disease: A systematic review".PloS one · 2022Pooled it
- Risk factors for acromion and scapular spine fractures after reverse total shoulder arthroplasty: a time-to-event analysis.Journal of shoulder and elbow arthroplasty · 2026Article
- Association of Bone Mass, Falls, and Vertebral Fractures in Older Patients on Hemodialysis: The Role of Comprehensive Geriatric Assessment.Journal of general internal medicine · 2026Article
- Exploring the potential application of roxadustat in chronic kidney disease-related osteoporosis based on the regulatory role of HIF-1α in bone metabolism.Histology and histopathology · 2026Review
- Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment-Naive Patients Compared With Zoledronate.Clinical pharmacology and therapeutics · 2026Article
- Impact of In-Hospital Osteoporosis Treatment on Post-discharge Medication Continuity in Osteoporotic Fracture Patients: Implications for Care Continuity.Clinics in orthopedic surgery · 2026Article
- Deciphering inter-organ communication: The multi-organ-bone axis in osteoporosis and emerging therapeutic strategies.Journal of orthopaedic translation · 2026Review
- The CKD-OSTEO Score: A Chronic Kidney Disease-specific Tool for Osteoporosis Risk Stratification.TouchREVIEWS in endocrinology · 2026Review
- Article
- Stattic engineering M2 macrophage-derived exosomes mediate autophagy and immune reprogramming for secondary hyperparathyroidism.Journal of advanced research · 2026Article
- Prevalence and risk factors of CKD-associated osteoporosis in maintenance hemodialysis patients aged over 50 years: a cross-sectional study.Scientific reports · 2026Article
- Article
- Interorgan Communications in Skeletal Pathophysiology: From Molecular Pathways to Multidisciplinary Therapies.Research (Washington, D.C.) · 2026Review
- Internal diseases and molecular mechanisms causing slipped capital femoral epiphysis in children.World journal of orthopedics · 2025Review
- Osteoporosis evidence landscape to inform policy and practice: A comprehensive scoping review.Journal of family medicine and primary care · 2025Review
- Recent advances in treatment options for kidney disease.Current opinion in nephrology and hypertension · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Chronic kidney disease (CKD) is associated with the development of mineral bone disorder (MBD), osteoporosis, and fragility fractures. Among CKD patients, adynamic bone disease or low bone turnover is the most common type of renal osteodystrophy. The consequences of CKD-MBD include increased fracture risk, greater morbidity, and mortality. Thus, the goal is to prevent the occurrences of fractures by means of alleviating CKD-induced MBD and treating subsequent osteoporosis. Changes in mineral and humoral metabolism as well as bone structure develop early in the course of CKD. CKD-MBD includes abnormalities of calcium, phosphorus, PTH, and/or vitamin D; abnormalities in bone turnover, mineralization, volume, linear growth, or strength; and/or vascular or other soft tissue calcification. In patients with CKD-MBD, using either DXA or FRAX to screen fracture risk should be considered. Biomarkers such as bALP and iPTH may assist to assess bone turnover. Before initiating an antiresorptive or anabolic agent to treat osteoporosis in CKD patients, lifestyle modifications, such as exercise, calcium, and vitamin D supplementation, smoking cessation, and avoidance of excessive alcohol intake are important. Managing hyperphosphatemia and SHPT are also crucial. Understanding the complex pathogenesis of CKD-MBD is crucial in improving one's short- and long-term outcomes. Treatment strategies for CKD-associated osteoporosis should be patient-centered to determine the type of renal osteodystrophy. This review focuses on the mechanism, evaluation and management of patients with CKD-MBD. However, further studies are needed to explore more details regarding the underlying pathophysiology and to assess the safety and efficacy of agents for treating CKD-MBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.